Checkpoint inhibitor-induced eosinophilic fasciitis following high eosinophilia associated with complete response
The DOI matches its Crossref record; 8 of the 9 references it cites were found in a registry or an index.
Abstract
Eosinophilic fasciitis is a rare immune-related adverse event associated with complete responses in melanoma patients. Sir, Checkpoint inhibitors induce a plethora of immune-related adverse events [1] including rare events. We report on a patient with debilitating eosinophilic fasciitis with accentuated eosinophilia possibly due to a higher risk from local dinitrochlorobenzene treatment prior to checkpoint inhibitor therapy. A 77-year-old female patient with acral lentiginous melanoma underwent complete right axillary lymph node dissection (0/21). Five months later several cutaneous metastases on the right arm and the thorax were found. Mutation analysis revealed BRAF wildtype, which excluded the possibility of a targeted therapy with BRAF inhibitors. A combined chemoimmunotherapy with dacarbazine and a contact sensitizer to boost the immune reaction against tumour antigens, local dinitrochlorobenzene, was started. However, the disease progressed and immunotherapy with an anti-cytotoxic T-lymphocyte-associated Protein 4 antibody (ipilimumab) was initiated. Two weeks after the second dose of ipilimumab, the patient developed grade 2 autoimmune diarrhoea in the Common Terminology Criteria for Adverse Events, meaning an increase of four to six stools per day over baseline, which was treated with prednisolone. Because of new cutaneous metastases, therapy was switched to an anti-programmed cell death receptor-1 antibody (pembrolizumab). Under pembrolizumab therapy she experienced…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“multiple recent reports of Eo-irAEs like eosinophilic fasciitis27-30 or eosinophilic granulomatosis with polyangiitis31 suggest that topical or low-dose oral corticosteroids, with or without CS-sparing treatments, can give excellent results.”
Citations
Cites
Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy
Hofmann, L., Forschner, A., Loquai, C., Goldinger, S. M., Zimmer, L., Ugurel, S., Schmidgen, M. I., Gutzmer, R., Utikal, J. S., Göppner, D., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.02.025 · Cited by 649
Self-citationDiagnosis and classification of eosinophilic fasciitis
Pinal-Fernandez, I., Selva-O' Callaghan, A., & Grau, J. M. (2014) · Autoimmunity Reviews · doi:10.1016/j.autrev.2014.01.019 · Cited by 209
Rheumatic manifestations among cancer patients treated with immune checkpoint inhibitors
Lidar, M., Giat, E., Garelick, D., Horowitz, Y., Amital, H., Steinberg-Silman, Y., Schachter, J., Shapira-Frommer, R., & Markel, G. (2018) · Autoimmunity Reviews · doi:10.1016/j.autrev.2018.01.003 · Cited by 180
Moreira, A., Leisgang, W., Schuler, G., & Heinzerling, L. (2017) · Immunotherapy · doi:10.2217/imt-2016-0138 · Cited by 147
Khoja, L., Maurice, C., Chappell, M., MacMillan, L., Al-Habeeb, A. S., Al-Faraidy, N., Butler, M. O., Rogalla, P., Mason, W., Joshua, A. M., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0186 · Cited by 109
Immune checkpoint inhibitor-induced myo-fasciitis
Daoussis, D., Kraniotis, P., Liossis, S. C., & Solomou, A. G. (2017) · Lara D. Veeken · doi:10.1093/rheumatology/kex369 · Cited by 25
Autoimmune fasciitis triggered by the anti-programmed cell death-1 monoclonal antibody nivolumab
Parker, M. J. S., Roberts, M., Lorigan, P. C., du Plessis, D., & Chinoy, H. (2018) · BMJ Case Reports · doi:10.1136/bcr-2017-223249 · Cited by 23
Eosinophilic fasciitis and lichen sclerosus in a patient treated with nivolumab
Andrés‐Lencina, J., Burillo‐Martínez, S., Aragón‐Miguel, R., Calleja‐Algarra, A., Rodríguez‐Peralto, J., Ortiz‐Romero, P., & Gargallo‐Moneva, V. (2018) · Australasian Journal of Dermatology · doi:10.1111/ajd.12836 · Cited by 23
Cited by
Kostine, M., Finckh, A., Bingham, C. O., Visser, K., Leipe, J., Schulze-Koops, H., Choy, E. H., Benesova, K., Radstake, T. R. D. J., Cope, A. P., et al. (2021) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-217139 · Cited by 290
Eosinophilic Fasciitis Following Checkpoint Inhibitor Therapy: Four Cases and a Review of Literature
Chan, K. K., MAGRO, C. M. J., Shoushtari, A. N., Rudin, C. M., Rotemberg, V. M., Rossi, A., Lezcano, C. M., Carrino, J. A., Fernández, D., Postow, M. A., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0508 · Cited by 78
Scanvion, Q., Béné, J., Gautier, S., Grandvuillemin, A., Le Beller, C., Chenaf, C., Etienne, N., Brousseau, S., Cortot, A. B., Mortier, L., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1722022 · Cited by 59
Kähler, K. C., Hassel, J. C., Heinzerling, L., Loquai, C., Thoms, K., Ugurel, S., Zimmer, L., & Gutzmer, R. (2020) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.14128 · Cited by 49
Self-citationKähler, K. C., Hassel, J. C., Heinzerling, L., Loquai, C., Thoms, K., Ugurel, S., Zimmer, L., Gutzmer, R., & (ADO), F. D. K. „. N. D. A. D. O. (2020) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.14128_g · Cited by 28
Self-citation
Metadata
- Authors
- Toussaint, F., Hammon, M., Erdmann, M., Moreira, A., Kirchberger, M. C., Schuler, G., Schett, G., & Heinzerling, L.
- Affiliations
- Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
- Corresponding author
- Heinzerling, Lucie
- ORCID
- Venue
- Rheumatology
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-05-05
- Volume
- 58
- Issue
- 10
- Pages
- 1875-1877
- ISSN
- 1462-0324 (ISSN-L)
- 1462-0332
- OpenAlex
- W2944325485
- Semantic Scholar
- 3f95545bc64b0bceb77fb46c4b63bf7454972764
- Cited by
- 19
- References
- 9
- Citations by year
- 2026: 3 · 2025: 2 · 2023: 1 · 2021: 4 · 2020: 7 · 2019: 2
- FWCI
- 1.37
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Lara D. Veeken (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Rheumatology › Eosinophilic Disorders and Syndromes
- Health Sciences › Medicine › Dermatology › Chemotherapy-related skin toxicity
- Keywords
- pembrolizumab, immune-related adverse events, immune checkpoint inhibitors, acral lentiginous melanoma, eosinophilia, autoimmune hepatitis, ipilimumab, 1-chloro-2,4-dinitrobenzene, chemoimmunotherapy, complete response, prednisolone, cutaneous metastasis
- MeSH terms
- Antineoplastic Agents, Immunological, Aged, Eosinophilia, Fasciitis, Female, Humans, Melanoma
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Checkpoint inhibitor-induced eosinophilic fasciitis following high eosinophilia associated with complete response. https://app.cochat.ai/papers/10.1093/rheumatology/kez164
- The paper
- Toussaint, F., Hammon, M., Erdmann, M., Moreira, A., Kirchberger, M. C., Schuler, G., Schett, G., & Heinzerling, L. (2019). Checkpoint inhibitor-induced eosinophilic fasciitis following high eosinophilia associated with complete response. Rheumatology. https://doi.org/10.1093/rheumatology/kez164
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.